Core--Quantitative Molecular Assay

在HIV相关神经系统疾病(手)中，HIV感染的巨噬细胞和FcGamma受体III (CD16)阳性的巨噬细胞和单核细胞与疾病有关 发病机制。然而，正常CD16+单核细胞之间的差异似乎在 补充组织巨噬细胞和功能失调的CD16+单核细胞似乎会促进炎症 定义不明确。病理有限责任公司最近开发了一种非常灵敏的分子检测方法 与严重的神经退行性疾病相关的功能障碍的巨噬细胞亚群及其推断 与艾滋病毒相关的神经系统疾病。在这项计划中，所有的研究项目都将得到资助 在他们的调查过程中广泛使用这种化验方法。相应地，该多基因表现为 实时定量逆转录-聚合酶链式反应将在病理科集中进行 这个项目项目。此外，病理组织将为所有人提供HIV和SIV的定量PCR检测 站点，包括HIV前病毒载量、SIV前病毒载量和SIV RNA。这些化验结果将允许 明确确定多胺生物合成抑制剂的治疗是否会显著影响艾滋病毒或 SIV复制。在一个地点进行这些艾滋病毒/SIV检测将有助于确保 所有研究项目的化验数据的重复性和质量，以及一些成本节约的结果。

In HIV associated neurological disease (HAND), HIV infected macrophages- and Fcgamma receptor III (CD16) positive macrophages and monocytes in particular, have been associated with disease pathogenesis. However, the differences between normal CD16+ monocytes that appear to have a role in replenishing tissue macrophages and dysfunctional CD16+ monocytes that appear to foster inflammation are not well defined. Pathologica LLC has recently developed a very sensitive molecular assay for the detection of the dysfunctional macrophage subset associated with severe neurodegenerative disease and by inference HIV associated neurological disease. In this program project grant all of the research proposals will make extensive use of this assay in the course of their investigations. Accordingly performance of this multi-gene real time quantitative reverse-transcription-PCR assay will be centralized at Pathologica during the course of this program project. Additionally, Pathologica will provide quantitative HIV and SIV PCR assays for all sites, including HIV proviral load, SIV proviral load, and SIV RNA. These assays will allow for an unambiguous determination if treatment with polyamine biosynthesis inhibitors significantly impacts HIV or SIV replication. The performance of these HIV / SIV assays at one location will help ensure the reproducibility and quality of the assay data for all research projects, as well as results in some cost savings.